The U.S. Centers for Disease Control and Prevention (CDC) awarded a $85,741,227.24 Firm Fixed Price Definitive Contract to Ginkgo Bioworks, Inc., a biotechnology company in Boston, Massachusetts, for a Traveler-Based Genomic Surveillance Program. The contract has an ultimate completion date of March 21, 2028 and was not set aside for a specific business category.
This contract appears to build on Ginkgo Bioworks' previous work with the CDC on COVID-19 genomic testing and surveillance at major U.S. international airports. The company has also provided a range of biotechnology services to various government agencies, including the Department of Defense, in areas such as pathogen detection, microbiome modulation, and biological manufacturing. Additionally, Ginkgo Bioworks holds a $118 million Indefinite Delivery/Indefinite Quantity (IDIQ) contract with the CDC for test surge and data sharing services, which further demonstrates the government's recognition of the company's capabilities in rapidly deploying advanced biotechnology solutions for public health challenges.
Generated 2/7/25, 9:17 AM